Regeneron Pharmaceuticals, Inc.
REGN
$892.48
$9.281.05%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 15.06% | 4.07% | 18.42% | -31.68% | -9.01% |
| Total Depreciation and Amortization | 7.21% | 2.23% | 3.62% | -0.60% | 8.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -162.82% | 500.62% | -84.62% | 414.50% | 136.27% |
| Change in Net Operating Assets | 68.07% | -136.53% | -133.75% | -36.94% | 157.25% |
| Cash from Operations | -2.21% | 8.99% | -25.24% | -20.48% | 173.48% |
| Capital Expenditure | -42.84% | -55.75% | 36.59% | -17.08% | -6.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 92.56% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 170.21% | 88.16% | -3,854.61% | 96.63% | -609.41% |
| Cash from Investing | 86.66% | 79.21% | -912.69% | 87.31% | -1,066.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.06% | 196.14% | -81.31% | 30.22% | 16.99% |
| Repurchase of Common Stock | -10.53% | 4.11% | 12.73% | -30.23% | 40.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -9.53% | 33.69% | -90.45% | -30.25% | 65.85% |
| Foreign Exchange rate Adjustments | 200.00% | 50.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 174.39% | 110.64% | -344.51% | 310.02% | -500.62% |
